Ton Buechner - Novartis Non-Executive Independent Director
| NVSEF Stock | USD 96.00 0.89 0.94% |
Director
Mr. Ton Buechner was NonExecutive Independent Director of Novartis Inc. since February 24, 2016. He is Member of the Audit and Compliance Committee. Mr. Buechner most recently served as chairman and CEO of the executive board of Dutch multinational Akzo Nobel from 2012 to 2017. Prior to joining AkzoNobel, he spent almost two decades at the Sulzer Corporation in Switzerland, where he was appointed divisional president in 2001 and served as president and CEO from 2007 to 2011. Mr. Buechners early career was spent in the oil and gas construction industry, and included roles at Allseas Engineering in the Netherlands and at Aker Kvaerner in Singapore. He is a member of the supervisory board of Voith GmbH in Germany. Mr. Buechner is an engineer by training. He received his masters degree in civil engineering from Delft University of Technology in the Netherlands in 1988, specializing in offshore construction technology and coastal engineering since 2016.
| Age | 53 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Castaigne | Sanofi ADR | 70 | |
| Bridgette Heller | Novartis AG ADR | 59 | |
| James Smith | Pfizer Inc | 61 | |
| Hans Wijers | GlaxoSmithKline PLC ADR | 64 | |
| Satoshi Suzuki | Santen Pharmaceutical Co | N/A | |
| Cornelia Bargmann | AstraZeneca PLC ADR | N/A | |
| Shantanu Narayen | Pfizer Inc | 57 | |
| Michel Demare | AstraZeneca PLC ADR | 62 | |
| Marla Salmon | Grifols SA ADR | N/A | |
| Nancy Andrews | Novartis AG ADR | 63 | |
| Igor Landau | Sanofi ADR | 70 | |
| Joseph Echevarria | Pfizer Inc | 64 | |
| Claudie Haignere | Sanofi ADR | 60 | |
| Srikant Datar | Novartis AG ADR | 67 | |
| Anita Hauser | Roche Holding Ltd | 49 | |
| Daniel Podolsky | GlaxoSmithKline PLC ADR | 61 | |
| Nazneen Rahman | AstraZeneca PLC ADR | N/A | |
| Laurent Attal | Sanofi ADR | 60 | |
| Paul Bulcke | Roche Holding Ltd | 64 | |
| Laurie Glimcher | GlaxoSmithKline PLC ADR | 69 | |
| Akio Kimura | Santen Pharmaceutical Co | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ton Buechner, Non-Executive Independent Director | ||
| Robert PharmD, Chief Officer | ||
| Verena Briner, Non-Executive Independent Member of the Board | ||
| Karen Hale, Chief Officer | ||
| Chris Ilsley, President CEO | ||
| Steven Baert, Head of HR | ||
| Richard Saynor, Chief Sandoz | ||
| Richard Francis, Member of the Executive Committee and Division Head, Sandoz | ||
| Daniel Vasella, Honorary Chairman of the Board | ||
| Pierre Landolt, Member of the Board of Directors | ||
| Elizabeth Doherty, Non-Executive Independent Director | ||
| Erwin Vanhaecke, Head Novartis Group Quality | ||
| Elizabeth Barrett, CEO, Novartis Oncology | ||
| Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | ||
| Charlotte PamerWieser, Corporate Secretary | ||
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
| Samir Shah, Global Head Investor Relations | ||
| David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals | ||
| Srikant Datar, Member of the Board of Directors | ||
| MarieFrance Tschudin, Pres Officer | ||
| Samir MD, Global Relations | ||
| Francesco Balestrieri, CEO of Sandoz, Member of the Executive Committee | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| Paul Penepent, Head Accounting | ||
| Joerg Reinhardt, Chairman of the Board | ||
| Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Brian McNamara, Member of the Management Board, Division Head, Novartis OTC | ||
| Michele Galen, Head Communications | ||
| Charles Sawyers, Non-Executive Independent Member of the Board | ||
| John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee | ||
| Dimitri Azar, Member of the Board of Directors | ||
| Frans Houten, Non-Executive Independent Director | ||
| Nancy Andrews, Non-Executive Independent Director | ||
| Susanne Schaffert, CEO Novartis Oncology, Member of the Executive Committee | ||
| Enrico Vanni, Member of the Board of Directors | ||
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
| Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee | ||
| Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland | ||
| Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Alex Krauer, Honorary Chairman of the Board | ||
| Michael Ball, CEO of Alcon, Member of the Executive Committee | ||
| Jeffrey George, Member of the Executive Committee and Division Head, Sandoz | ||
| Peter Kornicker, Chief Compliance Officer | ||
| Andreas Planta, Member of the Board of Directors | ||
| Joseph Jimenez, CEO, Member of the Executive Committee | ||
| Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director | ||
| William Winters, Non-Executive Independent Member of the Board | ||
| Ann Fudge, Member of the Board of Directors | ||
| George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility | ||
| Paul Arkel, Head of Corporate Strategy and External Affairs | ||
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
| Klaus Moosmayer, Chief Ethics Risk and Compliance Officer, Member of the Executive Committee | ||
| Felix Ehrat, General Counsel and General Counsel of Novartis International Ag | ||
| Harry Kirsch, Chief Officer | ||
| Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 207.39 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.00 X | |||
| Price To Book | 3.22 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Novartis Pink Sheet analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets |